# US 2008/0076824 A1 · Compounds That Inhibit Replication Of Human Immunodeficiency Virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076824 A1
- Document ID: US20080076824A1
- Status: Published application
- Kind: A1
- Application number: 11/660,429
- Filed: 2005-08-16
- Published: 2008-03-27
- Earliest claimed: 2004-08-18
- Inventors: Jan Balzarini; Anders Vahlne; Marita Hogberg; Weimin Tong
- Web page: https://patentgrep.com/patent/US20080076824A1

## CPC

- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 31/18: for HIV
- C07C 237/06: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HUV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.

## Claims

### Claim at position 1

-62. (canceled)

### Claim 63

A method of inhibiting in-vitro replication of human immunodeficiency virus (HIV) comprising providing an HIV inhibiting amount of a composition comprising as an active ingredient, with or without other active ingredients, a compound of formula N:
or a pharmaceutically acceptable salt, amide, or ester thereof; wherein A1 is Valine when A2 is hydrogen and A2 is Valine when A1 is hydrogen.

### Claim 64

A method of inhibiting in-vitro replication of human immunodeficiency virus (HIV) comprising providing an HIV inhibiting amount of a composition that comprises a compound of formula N:
or a pharmaceutically acceptable salt, amide, or ester thereof, wherein A1 and A2 are separately selected from the group consisting of a chain of 1 to 5 amino acids and hydrogen, to a cell culture infected with HIV.

### Claim 65 (depends on 64)

The method of claim 64, wherein A1 and A2 are separately selected from the group consisting of a chain of 1 to 3 amino acids and hydrogen.

### Claim 66 (depends on 64)

The method of claim 64, wherein A1 and A2 are separately selected from the group consisting of a chain of 1 to 2 amino acids and hydrogen.

### Claim 67 (depends on 64)

The method of claim 64, wherein A1 and A2 are separately selected from the group consisting of an amino acid and hydrogen.

### Claim 68 (depends on 64)

The method of claim 64, wherein A1 and A2 are separately selected from the group consisting of Valine and hydrogen.

### Claim 69 (depends on 64)

The method of claim 64, wherein the compound is Valine-alphahydroxyglycinamide.

### Claim 70 (depends on 64)

The method of claim 64, further comprising measuring the presence or absence of HIV or a marker thereof in said cell culture.

### Claim 71 (depends on 70)

The method of claim 70, wherein the presence or absence of HIV is measured by a p24 detection assay.

### Claim 72 (depends on 70)

The method of claim 70, wherein the presence or absence of HIV is measured by reverse transcriptase activity.

### Claim 73 (depends on 70)

The method of claim 70, wherein the presence or absence of HIV is measured by syncytia formation.

### Claim 74 (depends on 70)

The method of claim 70, wherein said composition is provided in a septum sealed vial.

### Claim 75 (depends on 70)

The method of claim 70, wherein said composition is provided in a container comprising a certification that said composition is a good manufacturing practice (OMP) formulation.

### Claim 76 (depends on 70)

The method of claim 70, wherein said composition is provided in a container comprising indicia of approval from a government agency.

### Claim 77

A method of inhibiting replication of human immunodeficiency virus (HIV) comprising:
identifying a subject in need of a compound that inhibits replication of HIV; and providing to said subject an HIV inhibiting amount of a composition comprising as an active ingredient, with or without other active ingredients, a compound of formula N:
or a pharmaceutically acceptable salt, amide, or ester thereof; wherein A1 is Valine when A2 is hydrogen and A2 is Valine when A1 is hydrogen.

### Claim 78 (depends on 77)

The method of claim 77, further comprising measuring the inhibition of replication of HIV.

### Claim 79 (depends on 77)

The method of claim 77, wherein said composition is formulated for oral administration.

### Claim 80

A method of inhibiting replication of human immunodeficiency virus (HIV) comprising:
identifying a subject in need of a compound that inhibits replication of HIV; and providing to said subject an HIV inhibiting amount of a composition comprising as an active ingredient, with or without other active ingredients, a compound of formula N:
or a pharmaceutically acceptable salt, amide, or ester thereof, wherein A1 and A2 are separately selected from the group consisting of a chain of 1 to 5 amino acids and hydrogen, to a cell culture infected with HIV.

### Claim 81 (depends on 80)

The method of claim 80, wherein A1 and A2 are separately selected from the group consisting of a chain of 1 to 3 amino acids and hydrogen.

### Claim 82 (depends on 80)

The method of claim 80, wherein A1 and A2 are separately selected from the group consisting of a chain of 1 to 2 amino acids and hydrogen.

### Claim 83 (depends on 80)

The method of claim 80, wherein A1 and A2 are separately selected from the group consisting of an amino acid and hydrogen.

### Claim 84 (depends on 80)

The method of claim 80, wherein A1 and A2 are separately selected from the group consisting of Valine and hydrogen.

### Claim 85 (depends on 80)

The method of claim 80, wherein the compound is Valine-alphahydroxyglycinamide.

### Claim 86 (depends on 80)

The method of claim 80, further comprising measuring the inhibition of replication of HIV.

### Claim 87 (depends on 80)

The method of claim 80, further comprising identifying said subject as one in need of a compound that inhibits replication of HIV.
